{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041322","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.801525+00:00","generated_at":"2026-06-11T18:03:25.174408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enliven Therapeutics Q2 2023 net loss $16.7M; cash $277.9M; Phase 1 data expected 2024","bullets":["Net loss of $16.7M for Q2 2023, compared to $8.9M in Q2 2022.","Cash, cash equivalents and marketable securities total $277.9M as of June 30, 2023.","R&D expenses $15.2M vs $7.9M; G&A expenses $5.0M vs $1.1M (year-over-year).","Phase 1 trials for ELVN-001 (CML) and ELVN-002 (HER2+) advancing with initial safety/efficacy data expected in 2024.","Third program product candidate selected; more details to be disclosed in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041322","json":"https://secwatch.observer/filing/0000950170-23-041322.json","markdown":"https://secwatch.observer/filing/0000950170-23-041322.md","text":"https://secwatch.observer/filing/0000950170-23-041322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/0000950170-23-041322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/elvn-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:03:25.174408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a816dc423337c6ad6619bd71e7586bb2e2273d3","claim":"Enliven Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $16.7 million.","evidence_excerpt":"Enliven reported a net loss of $16.7 million for the second quarter of 2023, compared to a net loss of $8.9 million for the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/0000950170-23-041322-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$16.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}